Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jane Grant-Kels MD, FAAD
Jane M. Grant-Kels MD, FAAD Advisory Board
Robert Brodell MD, FAAD
Robert T. Brodell MD, FAAD Editor-in-Chief
Sarah Chamlin MD
Sarah L. Chamlin MD Advisory Board
See All Experts
story of the week
Published in Dermatology

Journal Scan / Research · August 28, 2024

Effectiveness of 16-Week vs 8-Week Guselkumab Dosing in Maintaining Psoriasis Control in Super Responders

JAMA Dermatology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Joanna Twist MD

JAMA Dermatology
Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial
JAMA Dermatol 2024 Jul 31;[EPub Ahead of Print], K Eyerich, K Asadullah, A Pinter, P Weisenseel, K Reich, C Paul, R Sabat, K Wolk, S Eyerich, F Lauffer, J Angsana, FJH Taut, K Kohler, Y Chen, J Sendecki, MWL Leung, S Wegner, Y Personke, M Gomez, N Krüger, S Tabori, K Schäkel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated